• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

Here's My Take on Seattle Genetics

The firm is obviously fast becoming a real player in creating treatment for certain cancers. The firm still loses money.
By STEPHEN GUILFOYLE
Jun 22, 2020 | 11:00 AM EDT
Stocks quotes in this article: SGEN, MRK

I had heard the name before. Not really sure where, but to say that Seattle Genetics (SGEN) had been on my radar when Jim Cramer mentioned the firm almost two months ago on his Mad Money show would be a lie. New York was under attack. My neighborhood was under attack. I was under attack. The stock, the firm itself, was not one of the big pharmas or elite biotechs working on solving Covid-19 through either a vaccine or a therapeutic, and that was all I was worried about at that time. The shares would rally on Jim's positive mention. The selloff then rally again as Goldman Sachs added the name to that firm's "Conviction List" (with a $246 price target) in late May based on a number of promising cancer treatments that the firm has in their pipeline. Is it too late to jump on? The shares did run 6% on Friday. Let's take a look.

Then What?

Just a couple of days after the Goldman story, Seattle Genetics announced some positive exploratory results (including survival) for TUKYSA in patients suffering from HER2-positive metastatic breast cancer. The early results showed that these patients experienced a 42% reduction in the risk of death, and a 68% reduction in the risk of CNS disease progression or death. TUKYSA is meant to be a treatment in the fight against certain breast cancers where patients also develop a brain metastasis.

The firm also has another high profile candidate known as Padcev. Padcev has already been approved for the treatment of locally advanced bladder cancer. Seattle Genetics is cooperating with Merck (MRK) to combine Padcev with Merck's own blockbuster cancer drug, Keytruda.

Let's be honest. SGEN is already up threefold in just about nine months after being around for roughly 20 years. The firm is obviously fast becoming a real player in creating treatment for certain cancers. The firm still loses money. Earnings have been negative though revenue has been growing quite regularly. As a numbers guy, there are still a lot of good reasons to walk away and find somewhere else to place my hard earned dough. There are plenty of minus signs in places and you do not want to see them. EBITDA. Profit margin. EPS. A price to sales makes the shares look awfully expensive. Yet, technically, the set-up is there. Let's take a look.

The Chart

What do I see? I see a stock that ran literally from the low $90's in mid-March to roughly $168 in response to Jim's mention on his show. Since then, we have what is known as a Flat Base, which is a form of consolidation after a run like that. The base is supported at the bottom by our old friend, Fibonacci, and are finding resistance both on Friday as well as this morning at the pivot created in early May.

This is what I think. I do not buy them right here, right now. Either these shares will fail here, and come in yet again. Or, behind door number two, there is a breakout. To get there from here, we need to see a take and hold of $168. You give SGEN $168, I think SGEN might give you $220. That said, I would rather pay $173 than $166. Know what I mean?

(Seattle Genetics is a holding in Jim Cramer's Action Alerts PLUS member club. Want to be alerted before Jim Cramer buys or sells SGEN? Learn more now.)

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Stephen Guilfoyle was Long MRK equity.

TAGS: Drug Approvals | Investing | Stocks | Technical Analysis | Trading | Pharmaceuticals

More from Investing

Retailer Results Offer Clues as to the State of the Consumers They Serve

Bret Jensen
May 27, 2022 11:30 AM EDT

Some retailers are faring well while other are not, and it has a something to do with the income levels of their customers.

Urban Outfitters Is Showing No Signs of Renewal

Bruce Kamich
May 27, 2022 10:55 AM EDT

Shares of the retailer are likely to work still lower in the months ahead.

Look in the Basement for Bargains, If You Dare

Jonathan Heller
May 27, 2022 10:30 AM EDT

The ranks of companies trading below NCAV has been somewhat barren for a while, but you never know what you'll discover 'down there.'

Rocking a Trade in Live Nation

Ed Ponsi
May 27, 2022 10:00 AM EDT

You could improvise a trade in this concert name, but don't get yourself in a jam by becoming a total stock groupie.

Alibaba Shares Spurt Higher, but Drags on the Online Giant Lurk

Alex Frew McMillan
May 27, 2022 9:14 AM EDT

China's ongoing fight against COVID threatens to make the going tough for companies that do business there.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 10:58 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    "The Tremendous Power of the Sell Button"
  • 02:46 PM EDT STEPHEN GUILFOYLE

    We're Shedding Some of This Holding on Strength

    Check out the Stocks Under $10 portfolio here!
  • 11:33 AM EDT PETER TCHIR

    Thoughts Ahead of the Fed Minutes

    Recent economic and earnings issues are convincing...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login